A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
NCT: NCT06076642 · ACTIVE_NOT_RECRUITING
Brief Summary
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035). The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits. Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.
Frequently Asked Questions
What is A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases?
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases is a clinical trial registered under NCT06076642. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT06076642?
The current status of NCT06076642 (A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases) is: ACTIVE_NOT_RECRUITING.
When did A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases start?
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases started on 2024-11-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.